预后营养指数对铂类化疗耐药的转移性尿路上皮癌患者接受派姆单抗治疗的预测影响。
Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy.
机构信息
Department of Urology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
出版信息
Anticancer Res. 2021 Mar;41(3):1607-1614. doi: 10.21873/anticanres.14922.
BACKGROUND/AIM: We investigated the prognostic nutritional index (PNI), comprised of lymphocytes and albumin, as a potential prognosticator of metastatic urothelial carcinoma (mUC) patients receiving pembrolizumab.
PATIENTS AND METHODS
Sixty-five patients were retrospectively enrolled and classified as low (<40) and high (≥40) based on pretreatment PNI. Progression-free survival (PFS), overall survival (OS) and response rates were evaluated.
RESULTS
In the low PNI group, significantly shorter PFS and OS were observed. PNI was shown to be an independent predictor of PFS and OS in the multivariate analysis. C-index for both PFS and OS improved with the addition of PNI to the model described in the KEYNOTE-045 study. Significantly more patients experienced initial disease progression in the low PNI group.
CONCLUSION
PNI is a useful predictor of prognosis and disease progression in mUC patients receiving pembrolizumab.
背景/目的：我们研究了包括淋巴细胞和白蛋白在内的预后营养指数（PNI），作为接受派姆单抗治疗的转移性尿路上皮癌（mUC）患者的潜在预后指标。
患者与方法
回顾性纳入 65 例患者，并根据治疗前 PNI 将其分为低（<40）和高（≥40）组。评估无进展生存期（PFS）、总生存期（OS）和反应率。
结果
低 PNI 组的 PFS 和 OS 明显更短。多变量分析显示，PNI 是 PFS 和 OS 的独立预测指标。在 KEYNOTE-045 研究中描述的模型中加入 PNI 后，对 PFS 和 OS 的 C 指数均有所提高。低 PNI 组中更多的患者最初出现疾病进展。
结论
PNI 是接受派姆单抗治疗的 mUC 患者预后和疾病进展的有用预测指标。
Zotero 插件